Switching is not a given and a successful POM to P transition requires considerable research and planning to extend unique …
Amphista doses first patient in AML trial of protein degrader
Jennings becomes President of Beckman Coulter Diagnostics
Boyds expands Regulatory Affairs team to support growing demand

